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INTRODUCTION 
The insulin-like growth factors (IGF-I and IGF-II) are single-chain polypep­
tides with structural homology to proinsulin. They regulate proliferation and 
differentiation of a multitude of cell types and are capable of exerting 
insulin-like metabolic effects. Unlike insulin, they are produced by most 
tissues of the body and are abundant in the circulation. Thus the IGFs have 
the potential to act via endocrine as well as autocrine andlor paracrine 
mechanisms. 
The IGFs exert their effects at the cellular level by interacting with the 
Type-I IGF receptor (IGF-I receptor). They also bind to the Type II1mannose-
6-phosphate receptor (IGF-II receptor) and insulin receptors, as well as high 
affinity binding proteins (IGFBPs). Like the IGFs, the IGFBPs are produced 
by multiple cell types and have been shown to modulate IGF bioactivity. The 
recent availability of cDNA probes and antibodies for the IGFs, IGF receptors, 
and IGFBPs has led to a substantial increase in published studies of IGF 
physiology. This review attempts to integrate recent information regarding 
coordinate regulation and function of the IGFs, their receptors, and IGFBPs. 
BIOLOGICAL ACTIONS OF IOFS IN VITRO 
Effects on Growth and Differentiation 
The actions of the IGFs in stimulating growth and differentiation of a wide 
variety of cell types has been recently reviewed (70). Despite an extensive 
list of cell types that are responsive to the IGFs, the intracellular mechanisms 
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132 COHICK & CLEMMONS 
mediating these events are not defined. IGF-I acts as a progression factor in 
the cell cycle and synergizes with competence factors such as PDGF and FGF. 
Recent evidence indicates that ras proteins may be required for the mitogenic 
signal generated by IGF-I late in G I, whereas they are not essential for the 
action of PDGF or EGF during the Go/G 1 transition. In contrast, inhibition 
of the G protein alpha subunit inhibits the action of PDGF and EGF, but does 
not affect the IGF-I stimulation of DNA synthesis (72). 
IGF-I has been shown to stimulate terminal myogenic differentiation of L6 
myoblasts by inducing expression of the myogenin gene. The increase in 
myogenin mRNA levels in response to IGF-I is blunted by inhibitors of 
myogenic differentiation, and an oligodeoxyribonucleotide complementary to 
the amino terminal sequence of myogenin blocks the stimulation of differen­
tiation by the IGFs. The inhibition by the antisense oligomer is specific for 
differentiation, as none of the other anabolic effects of IGF-I on L6 myoblasts 
is affected (43, 44). 
Autocrinel P aracrine Actions 
While the liver is the major source of circulating IGFs, local production is 
thought to be important in the regulation of growth and differentiation. 
Induction of differentiation of skeletal muscle cells in vitro by serum 
withdrawal is associated with increases in IGF-II rnRNA levels and IGF-II 
cell-surface receptors (108, 129). Differentiation of muscle cells is inhibited 
by an oligonucleotide complementary to the first five codons of IGF-I1 and 
addition of IGF-II overcomes the inhibition, thus providing direct evidence 
that autocrine secretion of IGF-II stimulates myoblast differentiation (45). 
Muscle cells secrete several forms of IGFBPs in culture that may modulate 
the effect of the IGFs on differentiation. The secretion of IGFBP-5 is induced 
30-fold within 16 hr of the onset of differentiation in C2 skeletal muscle cells 
(128), while increased expression of IGF-II during differentiation is associated 
with decreased expression of IGFBP-2 and IGFBP-5 in mouse myoblasts (41). 
A shift in the pattern of IGFBP production has also been reported during 
differentiation of L6 muscle cells (86). 
Connective tissue cells have been shown to synthesize IOF-I, IGF-II, and 
IGFBPs in vitro, and growth hormone (GH), as well as other trophic 
hormones, regulates their synthesis at the tissue level. IGF-I and -II mRNAs 
are expressed in human dermal fibroblasts and in connective tissue stromal 
cells in multiple tissues (70). IGF-I rnRNA is expressed in chondrocytes of 
the epiphyseal growth plate of 28-day old rats. IGF-I mRNA levels are 
decreased in chondrocytes of hypophysectomized rats and partially restored 
by GH treatment (96), which supports a role for locally produced IGF-I in 
mediating the effect of GH on longitudinal bone growth. In addition to GH, 
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INSULIN-LIKE GROWTH FACTORS 133 
PTH stimulates rapid increases in IGF-I mRNA and peptide levels in 
osteoblasts, which may be mediated via increases in cAMP production (81). 
IGF-II synthesis by osteoblasts was constitutive in one study and not 
regulatable by PTH or other trophic agents (82); however, PTH stimulation 
of IGF-I and -II release from neonatal mouse calvaria has been reported (69). 
PTH also stimulates synthesis of IGFBP-4 via a cAMP-dependent mechanism 
in human osteoblasts (65). Since IGFBP-4 has been shown to inhibit the 
mitogenic effects of the IGFs in human osteoblasts, the acute effects of PTH 
on bone resorption could be mediated by the increased production of IGFBP-4 
(89). Release of IGF-II from mouse calvaria is stimulated by 1,25-(OH):z03 
to a similar extent as PTH, but release of IGF-I is inhibited (69). Estrogen 
also modulates IGF-I, IGFBP-2, and IGFBP-4 levels in osteoblasts, and 
estrogen stimulation of osteoblast proliferation is blocked by an antibody 
against IGF-I (21, 42). 
Genes for IGF-I and -II are expressed in human and rat ovary, however, 
cellular sites of synthesis vary between the two species. The granulosa cell is 
the primary site of IGF-I mRNA expression in the rat (57), whereas IGF-II 
transcripts are present in theca-interstitial cells, but not granulosa (58). Human 
luteinized granulosa cells express IGF-II mRNA, but not IGF-I mRNA, while 
IGF-I peptide is localized in the theca-interstitium (56). Estrogen treatment 
of immature, hypophysectomized rats increases ovarian levels of IGF-I mRNA 
while decreasing hepatic levels of IGF-I mRNA and ovarian IGF-II mRNA 
(57,58). In the rat ovary, the mRNAs for IGFBP-2, -3, and -4 are localized 
to interstitial cells, corpora lutea, and atretic granulosa cells, respectively, 
while IGFBP-5 mRNA is expressed in atretic granulosa cells, corpora lutea, 
and the surface epithelium (40, 95). IGFBP-l mRNA is not detectable in the 
rat ovary; however, it is present in the human ovary (63). Several forms of 
IGFBPs are secreted by granulosa cells in culture and have been shown to 
inhibit FSH stimulation of ovarian function (11, 130). Regulation of local 
production of IGF-I in the uterus may also be important . Estrogen induces 
IGF-I mRNA levels in the ovariectomized rat uterus, while decreasing IGF-I 
mRNA abundance in the liver, and IGF-I potentiates the effect of estrogen on 
DNA synthesis in rat uterus in organ culture (93). 
A number of human tumor cell lines have been shown to synthesize IGFs 
and IGFBPs and to have IGF-I or IGF-II receptors (75). Some of these cell 
lines grow in the absence of exogenous growth factors, and proliferation in 
serum-free media can be inhibited by antibodies that bind IGF-I, IGF-II, or 
the IGF-I receptor. Thus the IGFs may serve as autocrine regulators of tumor 
growth. Recently, IGF-II has been overexpressed in a breast tumor epithelial 
cell line (MCF-7), which does not constitutively express IGF-I or -II. 
IGF-I1-expressing clones showed marked morphological changes in anchor-
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134 COHICK & CLEMMONS 
age-dependent culture and grew in soft agar, while wild-type MCF-7 cells did 
not show these properties. An antibody against the IGF-I receptor inhibited 
the growth of IGF-II- expressing clones in serum-free medium (35). 
In summary, multiple cell types have been shown to synthesize the IGFs. 
Furthermore, antibodies against either IGF-I or -II or the IGF-I receptor have 
been shown to block bioactivity in several systems, thus indicating that 
autocrine/paracrine growth regulation is a likely possibility. Most of these cell 
types also secrete IGFBPs, although their specific functions in most systems 
remain to be determined. 
BIOLOGICAL ACTIONS OF IGFS IN VIVO 
Effects of IGF Infusion on Growth 
Infusion of IGF-I in GH-deficient, mature rats stimulates body weight gain, 
tibial epiphyseal width, and longitudinal bone growth. However, direct 
comparison with GH treatment indicates that GH is more potent (70). In one 
study, infusion of IGF-I or -II to neonatal hypophysectomized rats had no 
effect on body weight gain, despite normalization of serum IGF-I levels , while 
GH was stimulatory (52). Although GH treatment causes proportionate organ 
enlargement, IGF-I treatment consistently results in greater increases in 
kidney, spleen, and thymus weights (52, 70). These differences may be related 
to the distinct changes in serum IGFBP profiles that are induced by the two 
treatments. While IGF-I induces IGFBP-3, GH is required for production of 
the acid-labile subunit of the large molecular weight ternary complex. This 
complex is present in GH-treated, but not IGF-I-treated animals (136). This 
alteration in the carrier complex for IGF-I and -II may alter tissue delivery. 
It is also possible that these differences reflect direct effects of GH on tissue 
growth that are independent of its induction of IGF-I. 
Transgenic Animal Models 
Transgenic mice overexpressing the IGF-I gene have increased body weight 
gain compared to controls, but the increases are less than those of littermates 
expressing the GH gene (80). However, in these studies the levels of IGF-I 
in serum and certain organs were lower in the animals expressing the IGF-I 
gene compared to the GH-expressing animals. Recently, a transgenic line of 
mice expressing IGF-I has been crossed to a line of dwarf transgenic mice 
lacking GH-expressing cells (10). The mice that express IGF-I in the absence 
of GH grow larger than their GH-deficient transgenic littermates and exhibit 
weight gain and linear growth similar to that of their nontransgenic siblings. 
However, analysis of organ growth suggests that GH and IGF-I have some 
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INSULIN-LIKE GROWTH FACTORS 135 
effects that are distinct. GH appears to be necessary to attain normal liver 
size, while IGF-I can stimulate brain growth (10). 
Renal Function 
IGF-I peptide and mRNA are colocalized in the collecting duct epithelium, 
and IGF-I levels are regulated by GH. Levels of IGF-I peptide, but not IGF-I 
mRNA, rise in the kidney following unilateral nephrectomy in adult rats, 
which suggests that changes in translation or in clearance may be occurring 
(55). Expression of IGF-I and IGF receptor genes following unilateral 
nephrectomy has recently been shown to be age-dependent, with increases in 
mRNA levels of IGF-I, IGF-I receptor, and IGF-II receptor observed in 
remnant kidneys of immature, but not adult rats (91). While kidney cells have 
been shown to produce IGFBPs (28), their role in regulating the action of 
IGF-I in the kidney is largely unknown. However, IGF-I and IGFBP-I are 
colocalized in the same cell types in multiple nephron segments (62). 
Direct infusion of IGF-I increases kidney weight relative to somatic growth 
in several animal model systems (46, 66, 77) and increases glomerular 
filtration rate and renal plasma flow in humans (53). This suggests that IGF-I 
may be a physiologic regulator of renal function. Whether IGF-I has a role 
as a therapeutic agent in patients with renal insufficiency has not been 
determined. 
MODULATION OF IGF ACTION BY IGFBPS 
The IGFBP Family 
While attempting to purify IGF-I and -II from serum, investigators found that 
the IGFs were bound to higher molecular weight carrier proteins. Western 
ligand blotting, a technique that utilizes the binding properties of the IGFBPs 
for IGF-I or -II, has been used to obtain molecular weight estimates of several 
forms of IGFBPs and to determine which forms are present in multiple 
biological fluids (87, 107). Recently, cDNA cloning has been used to 
determine the sequences of the genes encoding each of the IGFBPs. 
The complete primary structures of six forms of IGFBP have now been 
determined. They have been designated IGFBP- l through 6. The mature 
proteins each consist of 200 to 300 amino acids, with signal sequences of 20 
to 40 amino acids. The IGFBPs have 18 cysteine residues in their amino- and 
carboxy terminal ends whose alignment is conserved, suggesting disulfide 
bonding may be important in forming the specific high-affinity IGF binding 
site. An exception is IGFBP-6, which lacks 2 and 4 of the homologous 
cysteines in the rat and human, respectively. In addition to the 18 cysteines, 
two additional cysteines are present in rat and human IGFBP-4. IGFBP-1  and 
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136 COHICK & CLEMMONS 
-2 contain an RGD sequence in their carboxy terminal end, which is found in 
many extracellular matrix proteins and often serves as a recognition sequence 
for cell surface integrin receptors. Four of the IGFBPs ( 3  though 6) are 
glycosylated to varying degrees, which may be important for adherence to cell 
surfaces. 
The first IGFBP to be completely characterized was human IGFBP-l .  This 
protein was purified from human amniotic fluid and decidua. The cDNA 
sequences of human and rat IGFBP-l are 58% homologous (87). IGFBP-l 
binds IGF-I and - I I  with approximately equal affinity. At pH 7.0 its affinity 
constant for IGF-I is fivefold greater than that of the IGF-I receptor. IGFBP-l 
mRNA expression is high in human decidua, endometrium, and fetal liver. In 
the adult rat, IGFBP-l mRNA expression is highest in the kidney, liver, and 
decidua (94). 
The complete structures of human, rat, and bovine IGFBP-2 have been 
determined from cDNA sequence analysis (16,87). The proteins from all three 
species are approximately 85% homologous. The liver is the predominant site 
of IGFBP-2 expression in the fetus, although kidney, stomach, lung, and brain 
also express moderate message levels. Expression is very high in rat brain and 
higher in fetal than adult tissues (101, 102). The affinity of IGFBP-2 for IGF-I I 
is threefold higher than for IGF-I, but its affinity for both is greater than that 
of IGFBP-l at pH 7.4. 
IGFBP-3 is the IGF-binding subunit of the 150 kd GH-dependent binding 
complex that is present in serum (8). IGFBP-3 was originally purified from 
human plasma, and its primary structure was determined from clones obtained 
from human liver cDNA libraries. Porcine, rat, and bovine IGFBP-3 have 
subsequently been cloned. In adult rats, abundant levels of IGFBP-3 are present 
in the kidney, liver, stomach, placenta, uterus, and ovary (2). IGFBP-3 has a 
very high affinity for both IGF-I and -I I and is the most abundant form of 
IGFBP in serum. These properties account for the fact that it binds greater 
than 95% of the IGF-I and -II in the circulation. 
IGFBP-4 has been purified from human and rat serum and from media 
conditioned by a human osteosarcoma cell line (61, 89, 115). Its primary 
structure has been determined from cDNA sequence analysis (61, 65, 114). 
The human and rat proteins are 92% homologous. While IGFBP-4 contains a 
single N-linked glycosylation site, it is generally present in a non-glycosylated 
form. Higher Mr forms of 28 to 30 kd have been detected in serum and 
conditioned medium of neuroblastoma cells (22, 61). A single mRNA 
transcript of 2.6 kb is present in multiple tissues of adult rats, with liver 
exhibiting the highest expression (95, 114). IGFBP-4 transcripts of 2.0 to 2.3 
kb have been detected in human tissues and fetal fibroblasts (19, 61, 65). 
IGFBP-4 has a high affinity for IGF-I and - I I  that is nearly equal to that of 
IGFBP-3 at pH 7.4. 
IGFBP-5 has been purified from human and rat sources ( 3, 7, 113), and its 
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INSULIN-LIKE GROWTH FACTORS 137 
primary structure has been obtained from clones isolated from rat ovary, human 
placenta, and human osteosarcoma cDNA libraries (60, 113). The rat and 
human proteins are 97% conserved, and MrS of the mature proteins are 28,428 
and 28,553, respectively (113). While IGFBP-5 contains no potential N-linked 
glycosylation sites, the protein migrates as a doublet at 31 to 32 kd on SDS 
gels under nonreducing conditions. IGFBP-S has the highest affinity for IGF-I 
and -II of all the IGFBPs, which is 50-fold greater than that of the IGF-I 
receptor at pH 7.4. 
A single 6.0 kb IGFBP-5 mRNA transcript has been detected in all tissues 
examined of adult rats. Several tissues have higher levels of mRNA compared 
to the liver, with the highest expression observed in the kidney (113). A single 
6.0 kb transcript is also present in human fetal fibroblasts (19). In addition to 
the 6.0 kb transcript, a 1.7 to 1.8 kb transcript has been detected in rat ovarian 
tissue and human osteosarcoma cells (40, 60). 
IGFBP-6 has been purified from several human sources, including serum, 
cerebrospinal f luid, and conditioned media of fibroblasts and osteosarcoma 
cells (3, 47, 79, 106, 137). The complete primary structure of rat and humali 
IGFBP-6 has been determined from cDNA sequence analysis of clones 
obtained from rat ovary, human placenta, and human osteosarcoma cells (61, 
112). The estimated MrS of the mature proteins are 22, 847 and 21,461 for 
the human and rat, respectively. The protein has a 10- to 100-fold higher 
affinity for IGF-II than for IGF-I (47, 79, 106), which is similar to the affinity 
of IGFBP-3 for IGF-1. A single transcript of 1.3 kb is abundant in all tissues 
that have been examined (112). 
The human IGFBP-l, 2, 3,4, and 5 genes are located on chromosomes 7, 
2, 7, 17, and 5, respectively (113). The human IGFBP-l, human IGFBP-3, 
and rat IGFBP-2 genes span 5.2, 8.9, and at least 8 kb, respectively, and have 
similar structural organization (17, 33, 34). The IGFBP-l and IGFBP-2 genes 
contain four exons, while the IGFBP-3 gene contains a fifth exon. The 
promoter regions of IGFBP-l and IGFBP-3 each contain a TAlA box and a 
consensus promoter element located upstream from a single mRNA cap site 
within a CpG island. Liver factor Bl (LFBI) appears to regulate basal IGFBP-l 
promoter activity in HepG2 cells by binding the CCAAT promoter element 
(126). This element is absent from the IGFBP-3 promoter, which contains 
sequences that could bind Spl and AP2. In contrast to IGFBP-l and -3, the 
IGFBP-2 gene lacks a T.tXfA box near the transcription start site. Its promoter 
region contains recognition sequences for several transcription factors includ­
ing Spl ,  ETF, AP-l, AP-2, and LFBI. 
Regulation of IGF Bioavailability 
The majority of IGF-I and -II in the circulation is associated with a lSO kd 
complex that is composed of glycosylated IGFBP-3, an 85 kd acid-labile subunit 
and IGF-I or -II (8). The acid-labile subunit and IGFBP-3 do not interact in the 
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138 COHICK & CLEMMONS 
absence of IGFs. The smaller Mr complex of 40 kd contains IGFBP-l, -2, -4, 
and -6 and contains most of the unsaturated IGF binding sites in serum (61, 
137). IGFBP-5 has not been identified in this complex; however, it has been 
purified from human serum and very small amounts are detectable in human 
and bovine serum by immunoblot analysis. Serum levels of IGFBP-3, -2, and 
-1 in the adult human are approximately 5 uglml, 150 ng/ml, and 50 ng/ml, 
respectively. The half-lives of the IGFs are dependent on their association with 
IGFBPS. The lO min half-life of 125I-IGF-I is extended to 30 min when bound 
to the 40,000 Mr complex and greater than lO to 15 hr when bound to the 
150,000 Mr complex. Radiolabeled des(1-3)IGF-I, which has reduced affinity 
for IGFBPs, is cleared more rapidly (4, 54). 
IGFBPs may also be important in mediating transport of the IGFs from the 
vascular space. IGFBP-1, -2, -3, and -4 have been shown to cross intact 
vascular endothelium, either alone or when crosslinked to IGF-I (6, 12a). 
However, it is not known whether the IGFs can also leave the vasculature in 
an unbound form. Insulin stimulates transport of IGFBP-l ,  but not IGFBP-2, 
across intact capillaries (5), which could be a mechanism by which insulin 
acutely lowers IGFBP-1 concentrations. 
Modulation of IGF Action at the Cellular Level 
IGFBPs both inhibit and potentiate the metabolic and mitogenic effects of the 
IGFs at the cellular level. Addition of purified IGFBP-I, -2, -3, or -4 inhibits 
binding of IGFs to cell surfaces and thus attenuates IGF bioactivity by 
sequestering the peptide and preventing receptor interaction (12, 18, 22, 32, 
48, 89, 109). At equimolar concentrations, IGFBP-3 is more effective than 
either IGFBP-2 or IGFBP- l  in blocking cell surface binding (84). 
Preincubation of fibroblasts with IGFBP-3 results in potentiation of IGF-I 
activity, while co-incubation of IGFBP-3 and IGF-I is inhibitory (8, 32). The 
potentiating effect is associated with increased binding of IGF-I to membrane­
associated IGFBP- 3 (32). IGFBP-3 released from cell surfaces of fetal 
fibroblasts has a greater affinity for IGF-I than that remaining on the cell 
surface (85). Therefore, the potentiating effect of cell-surface associated 
IGFBP-3 may be the result of a decrease in its binding affinity, which would 
permit a more favorable equilibrium with the IGF-I receptor. The mechanism 
by which IGFBP-3 adheres to cell surfaces is unknown, but does not appear 
to require glycosylation (31). 
IGFBP-l and -2 also potentiate the mitogenic activity of IGF-I; however, 
IGFBP-1 is more potent than IGFBP-2 and also induces a greater increase in 
IGF-I binding to the cell surface (16, 24). Two forms of IGFBP-l have been 
isolated from amniotic fluid, but only one form potentiates IGF-I activity, and 
this form associates with cell membranes (87). The mechanism by which 
cell-surface associated IGFBPs potentiate IGF activity is unknown. Studies 
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INSULIN-LIKE GROWTH FACTORS 139 
with IOF analogues with altered affinity for IGFBPs and the IOF-I receptor 
indicate that binding of IGF-I to both IGFBP-l and the IGF-I receptor is 
required for potentiation (23). 
IGFBP-5 has been shown to potentiate the proliferative actions of IGF-II 
in osteoblasts (7), while a mixture of IGFBP-5 and -6 enhances IGF-I 
stimulation of mitogenesis in human osteosarcoma cells (3). Preincubation 
with the IGFBPs was not necessary to elicit the potentiating effect on IGF 
activity, and their ability to associate with cell membranes was not detennined. 
IOFBP-l is phosphorylated in vitro by human hepatoma (HepG2) and 
endometrial cells in culture (49, 59). Human amniotic f luid and fetal serum 
contain both nonphosphorylated and phosphorylated IGFBP-1, whereas 
HepG2 and decidual cells secrete predominantly phosphorylated isoforms. The 
phosphorylated IGFBP-1 secreted by HepG2 cells has a sixfold higher affinity 
for IGF-I than it does after dephosphorylation. IGFBP-3 is also phosphorylated, 
however, its affinity for IOF-I has not been determined. Dephosphorylated 
IGFBP-l purified from amniotic f luid potentiates the effect of IGF-I on DNA 
synthesis, while the phosphorylated form appears to be inhibitory. 
REGULATION OF IGF AND IGFBP SYNTHESIS 
Hormonal Regulation 
The regulation of circulating concentrations and tissue synthesis of IGF-I by 
GH is well documented (8, 36). Circulating levels of IGFBP-3 are also 
regulated by GH; however, this effect is likely mediated by IGF-I since 
infusion of IGF-I to hypophysectomized rats induces IGFBP-3 (26, 136). 
While serum levels of IGF-I and IGFBP-3 decrease in a coordinate fashion 
in hypophysectomized rats, mRNA levels are not coordinately regulated in 
all tissues. In liver, mRNA levels of IOF-I and IGFBP-3 are decreased to 10 
and 50% of controls, respectively, and partially restored with GH treatment. 
Levels of IGF-I mRNA in the kidney follow a similar pattern; however, kidney 
IGFBP-3 mRNA levels increase twofold in hypophysectomized rats and are 
not reduced by GH (2). Synthesis of IGFBP-3 by multiple cell types including 
chondrocytes, fibroblasts, endometrial and breast carcinoma cells is also 
stimulated by IGF-I or -II (20, 23, 111). TGF-beta also stimulates IGFBP-3 
secretion by human skin fibroblasts (78). 
In contrast to IGFBP-3, blood levels of IGFBP-2 are inversely related to 
GH status. IGFBP-2 levels increase twofold in patients with hypopituitarism 
(25), and decrease fourfold in lactating dairy cows treated with GH (29). 
However, GH does not affect IGFBP-2 levels in calorically restricted adults, 
which suggests that a normal caloric intake is required for GH to suppress 
IGFBP-2 (25). Infusion of IGf-I in healthy adults increases circulating 
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IGFBP-2, while patients with non-islet cell tumor hypoglycemia, in which 
IGF-II is overexpressed, also have elevated IGFBP-2 levels (137). Thus, GH 
and IGF-I appear to regulate IGFBP-2 in a dis-coordinate manner. 
IGFBP-4 secretion is decreased following exposure to IGF-I or -II in fetal 
fibroblasts and breast carcinoma cells, while insulin at concentrations suffi­
cient to stimulate the IGF-I receptor increases secretion of IGFBP-4 (19,20). 
However, this effect appears to be cell-type specific since IGF-I stimulates 
IGFBP-4 secretion in L6 muscle cells (86). The decrease in IGFBP-4 secretion 
by fetal fibroblasts that occurs with IGF-I treatment is not accompanied by a 
decrease in mRNA abundance (1 9). 
There are presently no reports on regulation of IGFBP-5 in vivo. The 
findings that hepatic abundance of IGFBP-5 mRNA is low and that serum 
contains very little detectable protein suggest that circulating IGFBP-5 has a 
minor regulatory role. In contrast, IGFBP-5 that is synthesized by connective 
tissue cells and localized in extracellular matrix may be important. IGF-I 
increases IGFBP-5 abundance in fibroblast conditioned media six- to eightfold 
while causing no change in mRNA levels. In addition, insulin, at doses that 
should act through the IGF-I receptor, fails to increase IGFBP-5Ievels, which 
indicates that IGF-I is not acting via its receptor to stimulate IGFBP-5 secretion 
(19). This effect is mediated by a unique mechanism whereby fibroblasts 
secrete a protease that specifically degrades IGFBP-5. When IGF-I or -II binds 
to IGFBP-5, degradation is inhibited. 
IGFs and IGFBPs have been suggested to play a role in the growth inhibitory 
effects seen with glucocorticoid excess. Dexamethasone reduces body weight 
gain and hepatic and tibial IGF-I mRNA abundance in the adult rat without 
affecting serum IGF-I concentrations, while at the same time increasing 
IGFBP-l serum and hepatic mRNA levels (73). Hepatic IGFBP-l mRNA levels 
are also increased during dexamethasone-induced growth retardation in fetal 
rats, however, mRNA levels of IGF-I and -II are not decreased (104). 
Dexamethasone increases IGFBP-l mRNA levels by increasing gene transcrip­
tion (103,  131). Treatment of 4-day old rats with dexamethasone decreases 
both hepatic IGF-II and IGFBP-2 mRNA levels (102), while treatment of 
4-week old rats increases serum and hepatic mRNA levels of IGFBP-3 (74). 
Secretion of IGFBP-3 and IGFBP-5 by fetal fibroblasts in vitro is decreased 
by dexamethasone (19). 
Nutritional Regulation 
Adequate nutrition is essential for IGF-I to promote growth. During under­
nutrition, attenuation of growth is accompanied by decreases in serum IGF-I 
that cannot be normalized by GH treatment (27). The decline in IGF-I 
concentrations during fasting is due to a decrease in binding of GH to its 
hepatic receptor. These changes are accompanied by decreases in hepatic 
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INSULIN-LIKE GROWTH FACTORS 141 
IGF-I and GH receptor mRNA abundance (15, 120). A reduction in the rate 
of IGF-I gene transcription does not account for the decrease in IGF-I mRNA, 
which suggests that regulation is  primarily at the posttranscriptional level 
(120). Reductions in IGF-I and GH receptor mRNA levels are also observed 
in nonhepatic tissues, although the two mRNAs are not coordinately regulated 
in all tissues (15, 71). IGF-I receptor mRNA appears to be up-regulated in 
several tissues (71). IGF-I treatment has been shown to partially restore the 
growth rate of malnourished rats (110) , thus suggesting that some degree of 
tissue sensitivity to IGF-I is maintained. 
In contrast to the decrease in hepatic GH binding observed during fasting, 
dietary protein restriction appears to cause GH resistance by a postreceptor 
mechanism (27). Reductions of IGF-I mRNA levels in liver and skeletal muscle 
are observed during protein restriction in growing rats (121, 132). However, 
infusion of IGF-I into protein-restricted rats fails to normalize tail length, 
weight, or tibial epiphyseal width despite normalization of serum IGF-I levels 
and enhancement of spleen and kidney growth (127). This suggests that dietary 
protein restriction causes organ-specific resistance to IGF-1. 
Serum levels of IGF-I, IGFBP-3, and IGFBP-2 are relatively constant over 
the day. In contrast, IGFBP-l levels show a marked diurnal variation that is 
inversely related to insulin status and blood glucose levels and is independent 
of GH secretory status. The regulation of IGFBP-l in serum has been 
extensively studied, and a role in glucose counter-regulation has been proposed 
(67). Administration of an IGF-I1IGFBP-l complex to rats blocks the 
hypoglycemic response to exogenous IGF-I , while injection of IGFBP-l alone 
increases plasma glucose levels (68). These data suggest that the IGFs may 
play a role in glucose homeostasis. The effects of insulin on IGFBP-l appear 
to be both direct, as well as secondary, to changes in glucose concentrations 
(116, 124) . 
Alterations in IGFBP-l levels due to metabolic status are reflected at the 
level of hepatic synthesis , although insulin has also been shown to stimulate 
transport from the vasculature. Hepatic IGFBP-l production is increased by 
glucagon, substrate deprivation, and factors that increase cAMp, whereas 
insulin is inhibitory (67). Insulin decreases IGFBP-l mRNA levels in rat 
hepatoma cells by directly decreasing gene transcription (131). Therefore, the 
regulation of hepatic IGFBP-l synthesis may be an important determinant of 
serum IGFBP-l levels. 
Extreme variations in nutrient intake such as fasting also regulate IGFBPs. 
Plasma levels of IGFBP-3 are decreased by fasting or protein deprivation in 
growing rats (26), while hepatic mRNA levels of IGFBP-2 and IGFBP-I are 
increased by fasting or protein deprivation (94, 10 1, 102, 121). Maternal 
fasting increases IGFBP-l mRNA levels in fetal liver, while having no effect 
on IGFBP-2 mRNA levels (119). Levels of IGFBP-l are increased in serum 
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142 COHICK & CLEMMONS 
of neonatal piglets after 48 hr of fasting when analyzed by ligand blot and 
radio-immunoassay (RIA). In contrast, IGFBP-21evels are increased by RIA, 
but decreased by ligand blot analysis, which indicates that an IGFBP-2-specific 
protease may regulate IGFBP-2 levels in neonatal serum (88). 
Developmental Regulation 
The IGFs are believed to be important in fetal development, and direct 
evidence of a role for IGF-II in fetal growth has been demonstrated (38). 
IGF-I and -II mRNA transcripts are present in virtually all fetal tissues, 
although their abundance and ontogeny of expression varies among organs. 
In the fetal rat, IGF-II gene expression is abundant in most tissues, but 
decreases dramatically at birth in all tissues except the brain. The decrease in 
IGF-II mRNA levels corresponds to the decrease in circulating levels of IGF-II 
postnatally. However, this decrease may be unique to the rat, as studies in 
other species, induding humans, have shown that significant serum levels of 
IGF-II are maintained postnatally. IGF-I transcripts in fetal liver, kidney, and 
heart are lower in abundance compared with IGF-I1 and rise progressively 
with increasing postnatal age, as does serum IGF-I, while expression in fetal 
lung, muscle, and stomach is higher than it is postnatally (1). In mid-gestation, 
IGF-I and -II transcripts are found predominately in mesenchymal cells; 
however, early in organogenesis these transcripts are not always coexpressed, 
and in the case of IGF-II, not restricted to cells of mesenchymal origin (14). 
Levels of IGFBP-I and -2 are also developmentally regulated, with 
transcripts for each expressed in a variety of fetal tissues. Expression of both 
mRNAs is higher in the liver than in other fetal tissues, with abundant levels 
of IGFBP-2 also present in fetal kidney, brain, and stomach (101). IGFBP-2 
transcripts are predominately localized to cells of ectodermal and endodermal 
origin and expressed in discrete locations in the nervous system during early 
organogenesis. They are not colocalized with IGF-II mRNA (135). Message 
and serum levels of IGFBP-I and -2 fall postnatally in the rat. IGFBP-3 is 
not present in serum of fetal rats; however, IGFBP-3 mRNA is present in the 
kidney and liver of I-day old rats and increases in both organs by week I. 
Levels remain constant thereafter, while the levels of hepatic IGF-I mRNA 
continue to increase up to 8 weeks (2). In contrast to the rat, IGFBP-3 levels 
are abundant in fetal serum of other species, such as the sheep, co�, and pig, 
although circulating concentrations are significantly higher in postnatal life. 
IGFs and IGFBPs are altered in maternal serum during pregnancy. In the 
rat, serum IGF-I and hepatic IGF-I mRNA levels are decreased during 
pregnancy, while serum IGF-II levels are unchanged (37, 39). In the human, 
serum IGF-I and IGFBP-31evels determined by RIA increase during pregnancy 
(8). In contrast, IGFBP-3 is virtually undetectable by ligand blot analysis in 
pregnant serum of both humans and rodents (37, 39, 50). This decrease has 
A
nn
u.
 R
ev
. P
hy
sio
l. 
19
93
.5
5:
13
1-
15
3.
 D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 U
ni
ve
rs
ity
 o
f N
or
th
 C
ar
ol
in
a 
- C
ha
pe
l H
ill
 o
n 
04
/0
4/
18
. F
or
 p
er
so
na
l u
se
 o
nl
y.
 
INSULIN-LIKE GROWTH FACTORS 143 
been attributed to the presence of a protease that would produce fragments 
that are unable to bind the IGFs, but would react immunologically (37,51). 
However, this discrepancy has also been attributed to an alteration in the ability 
of IGFBP-3 to bind iodinated IGF (122, 123). The exact physiological role 
that this protease plays in IGF function during pregnancy is not clear. The 
abundance of liver IGFBP-3 mRNA is not altered during preganancy in the 
rat, while IGFBP-l and -4 mRNA levels are increased (39). 
THE IGF-I RECEPTOR 
The IGF-I receptor mediates most of the biological actions oflGF-I and IGF-II 
and is present in a wide variety of tissues and cell lines. The affinity (kd) of 
the IGF-I receptor for IGF-I is approximately 1 nM, 2- to 10-fold lower for 
IGF-II, and 100- to 500-fold lower for insulin. The IGF-I receptor is an 
alpha2beta2 transmembrane glycoprotein that is structurally similar to the 
insulin receptor and contains tyrosine protein kinase domains in the cytoplas­
mic portion of the beta subunit. The gene is located on human chromosome 
15 and mouse chromosome 7 (125). Promoters of the human and rat IGF-I 
receptor genes lack TAT A and CAA T boxes upstream of a unique transcription 
start site and contain potential binding sites for several transcription factors 
(76, 133). 
1GF -1 Receptor Function 
Expression studies of cloned IGF-I and insulin receptor cDNAs indicate that 
both receptors are capable of mediating short-term metabolic effects, as well 
as long-term mitogenic effects. The physiological roles of both insulin and 
IGF-I are therefore likely to be determined by the distribution and abundance 
of their receptors on the cell surface. However, studies with chimeric receptors 
containing the extracellular ligand-binding domain of the insulin receptor and 
the intracellular domain of the IGF-I receptor indicate that while the IGF-I 
and insulin receptors mediate short-term responses such as glucose transport 
similarly, receptors containing an IGF-I intracellular domain are more 
effective in stimulating DNA synthesis than the insulin receptor (64). Thus, 
insulin and IGF-I receptors have similar, yet distinct, signaling potentials that 
are defined by the cytoplasmic domain. 
The intrinsic tyrosine kinase activity of the IGF-I receptor may mediate the 
biological actions of IGF-I by phosphorylating endogenous cellular substrates. 
Several substrates for IGF-I receptor kinases have been identified. The 
phosphoprotein pp 185 is an endogenous substrate of both the IGF-I and insulin 
receptor kinases. This protein has recently been purified and sequenced and 
is now designated Insulin Receptor Substrate-! (IRS-I) (109a, 124a). IRS-l 
has been proposed as a multi-site "docking" protein, which upon phosphory-
A
nn
u.
 R
ev
. P
hy
sio
l. 
19
93
.5
5:
13
1-
15
3.
 D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 U
ni
ve
rs
ity
 o
f N
or
th
 C
ar
ol
in
a 
- C
ha
pe
l H
ill
 o
n 
04
/0
4/
18
. F
or
 p
er
so
na
l u
se
 o
nl
y.
 
144 COHICK & CLEMMONS 
lation associates with cellular proteins such as phosphatidylinositol 3' kinase, 
most likely through src-homology 2 (SH2) domains (20a). The phosphoprotein 
pp175 is also an endogenous substrate for the IGF-I and insulin receptors in 
FRTL5 thyroid cells and in L6 myoblasts in which it is associated with the 
cytoskeleton (9, 30). In undifferentiated L6 cells, stimulation by IGF-I 
increases IGF-I receptor phosphorylation and pp175 induction, whereas 
IGF-I-induced phosphorylation of pp 175 is almost undetectable after cells 
differentiate into myotubes. Sequence analysis of pp175 will determine 
whether this protein is identical to IRS-I, which appears likely. The ability 
of IGF-I to stimulate mitogenesis, but not glucose transport, is inhibited in 
cells expressing a kinase-defective insulin receptor. IGF-I mediated phosphor­
ylation of pp170 and pp220 is inhibited in these cells (83). Therefore, while 
the specific functions of phosphorylated endogenous substrates are unknown, 
evidence that they may be important mediators of biological activity is 
accumulating. 
IGF-I Insulin Receptor Hybrids 
Some tissues and cell types have been shown to express hybrid receptors 
composed of one insulin receptor alpha and beta subunit and one IGF-I 
receptor alpha and beta subunit. These receptors may account for the 
appearance of two beta subunits with different Mr that are frequently observed 
following IGF-I stimulation. The presence of hybrid receptors was suggested 
by findings that monoclonal antibodies specific for the insulin receptor 
immunoprecipitated IGF-I binding activity (117). Evidence that this cross­
reactivity is produced by hybrid receptors came from studies in which an 
antibody specific for the human insulin receptor immunopreciptiated IGF-I 
binding activity only after expression of the human insulin receptor in rodent 
cell lines and, conversely, an antibody specific for the human IGF-I receptor 
acquired the ability to immunoprecipitate inSUlin-binding activity following 
expression of human IGF-I receptors in a mouse cell line (118). The hybrid 
receptor has higher affinity for IGF-I than insulin, and IGF-I is more effective 
than insulin in inducing a conformational change in the receptor and in 
activating autophosphorylation (90, 118). Therefore, the hybrid receptor 
appears to function more as an IGF receptor than as an insulin receptor . The 
extent to which hybrid receptors constitute the total receptor population has 
not been defined for most systems. However, in placenta, 70% of the receptors 
are estimated to be hybrids (117). This suggests that in some tissues these 
receptors may play an important role in coordinating IGF action. 
Developmental Regulation 
Levels of IGF-I receptor mRNA decrease in multiple tissues throughout 
postnatal development in the rat in comparison to fetal levels. In contrast, 
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INSULIN-LIKE GROWTH FACTORS 145 
IGF-I mRNA levels increase in liver, heart, and kidney postnatally (134). 
During early organogenesis, mRNA for the IGF-I receptor is widely distrib­
uted in fetal tissues and is most prominent in the developing nervous system 
and muscle. IGF-I1 rnRNA is also widespread and more abundant than IGF-I 
message, which is relatively localized, suggesting that the actions of IGF-II 
may be mediated via the IGF-I receptor in the fetus (14). Recently, two cellular 
patterns of IGF-I receptor gene expression have been described during 
development of the rat brain (13). Cells of neuroepithelial lineage have a basal 
level of receptor gene expression that could represent a target for IGFs in CSF 
and mediate a basic metabolic or trophic function. Superimposed on this 
constitutive pattern are sets of neurons that show high levels of IGF-I receptor 
rnRNA in conjunction with IGF-I mRNA expression during the period of 
postnatal differentiation. This suggests that these may represent specific areas 
of paracrine IGF-I action in the brain parenchyma (13). 
THE IGF-II RECEPTOR 
Physiological Significance 
The IGF-II receptor is identical to the cation-independent mannose-6-phos­
phate (M6P) receptor, which functions as a lysosomal enzyme targeting 
protein. This receptor consists of a single polypeptide chain with a large 
extracellular domain containing separate binding sites for IGF-II and M6P, a 
very short cytoplasmic region that lacks intrinsic protein kinase activity, and 
a single transmembrane domain. The majority of the metabolic and mitogenic 
effects of IGF-Il are mediated through the IGF-I or insulin receptors. The 
limited studies that indicate a role for the IGF-II receptor in mediating the 
biologic responses of IGF-Il are difficult to interpret and have been recently 
reviewed (98). Therefore, the function of the IGF-II receptor with respect to 
IGF-II growth promoting activity remains to be elucidated. 
Signal Transduction 
Recently, the IGF-II receptor has been shown to be coupled to Gh, a 
GTP-binding protein (G protein). In phospholipid vesicles, IGF-II directly 
couples purified rat IGF-II receptor with porcine Giz (97). In reconstituted 
vesicles containing clonal human IGF-I1 receptor and purified G proteins, the 
stimulatory effect of IGF-II on Giz activation is inhibited by M6P, while Gh 
is not activated by M6P alone (92). A 14 amino acid segment of the 
cytoplasmic domain of the IGF-I1 receptor is able to activate Gh, and its 
activation is blocked by an antibody against this segment (99, 100). Further 
evidence that IGF-II may signal intracellular events by activating G proteins 
via the IGF-II receptor comes from the finding that low concentrations of 
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146 COHICK & CLEMMONS 
IGF-II stimulate production of inositol triphosphate in kidney proximal tubular 
membranes (105). However, this effect is potentiated by M6P, which indicates 
that the G protein involved may not be analagous to Gil. The relationship of 
this G protein signaling mechanism to the IGF-related growth response has 
not been defined. 
SUMMARY 
The recent availablity of reagents to study the IGPs, their receptors, and 
binding proteins has led to an explosive growth in the study of IGF physiology. 
However, most studies to date have been descriptive, and studies delineating 
mechanisms of action are limited. It is apparent that most organ systems 
synthesize several components of the IGF system necessary for IGF to function 
in an autocrine or paracrine fashion and that regulation of this system occurs 
at the local level. However, the relative importance of locally produced IGF 
vs circulating IGF remains unclear. The mechanisms by which the IGFBPs 
modulate IGF activity are crucial to understanding this system, and identifi­
cation of specific roles for each of these proteins will be required. Of critical 
importance is the identity of the intracellular signal transduction system by 
which the IGF receptor mediates the effects of the IGFs, and the delineation 
of mechanisms by which the IGFBPs interact with the receptor at the cellular 
level. It is also of interest to detennine what role, if any, the IGF-II receptor 
plays in mediating the growth-promoting effects of the IGFs. 
The ubiquitous distribution of the IGFs, IGFBPs, and IGF receptors 
indicates that they may play a role in the regulation of coordinate growth 
amoung several tissues and cell types. Understanding the mechanisms by 
which these components interact to coordinate growth responses between 
different cell types should greatly enhance our understanding of nonnal growth 
and development. 
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